Stay updated with breaking news from ஸெநெக ப்ல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AstraZeneca invests in Imperial's self-amplifying RNA technology with eye on future drugs reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Innate Pharma Shares Rise After AstraZeneca Presents Positive Data From NSCLC Trial to European Conference streetwisereports.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetwisereports.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca Plc's Covid-19 antibody cocktail was found to be 77% effective in preventing symptomatic Covid-19 in high-risk people in a key trial that could expand the range of drugs available to vulnerable groups. ....
Malaysia gets another half a million AstraZeneca vaccine doses today themalaysianreserve.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themalaysianreserve.com Daily Mail and Mail on Sunday newspapers.
(Bloomberg) AstraZeneca Plc said its coronavirus antibody cocktail was found to be 77% effective in preventing symptomatic Covid-19 in high-risk people in a key trial, and the U.K. approved a rival’s drug as its first antibody treatment for the disease. Results from Astra’s study found no one in the trial who received the cocktail contracted severe Covid-19 or died in relation to the virus, the company said in a statement Friday. The trial of 5,197 participants, which started in November, was looking at whether the drug could prevent infection in at-risk groups such as transplant patients and those undergoing chemotherapy. The result comes as the U.K. approved its first monoclonal antibody drug against Covid-19 Friday, giving a green light to a treatment from Regeneron Pharmaceuticals Inc. and Roche Holding AG. The product was first authorized in the U.S. in November and European authorities have said they’re on track to complete their review this year. Demand has jumped amid t ....